Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

NCT00651612 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

604

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma
Ocular Hypertension

Interventions

DRUG: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
DRUG: Concurrent brimonidine 0.2% and 0.5% timolol

Sponsor

Allergan